Exploration of MRI measures of neurodegeneration within individuals over short intervals
Document text
Principal Investigator: RANDY L BUCKNER Organization: HARVARD UNIVERSITY Fiscal Year: 2024 Award: $558,231 Funding agency: National Institute on Aging PROJECT ABSTRACT/SUMMARY Alzheimer's disease and other forms of dementia affect over five million Americans. Alzheimer's disease begins with changes in the brain more than a decade before the disease can be diagnosed from memory and cognitive impairment in a clinic. The goal of this work is to provide a way to measure early signs of neurodegeneration in individual people. The historical barrier to measure change in individuals is that each person's brain is different with change accumulating too slowly to be picked over short intervals. As a result, most research focuses on tracking averaged subject groups or tracking change over multiple years. The present work optimizes new brain imaging techniques using MRI to make extremely fast, highly precise repeated measurements of brain regions all within the same individual. The work then seeks to use the novel imaging approach to measure neurodegeneration in individuals with early stages of Alzheimer's disease in six months or less and also differentiate changes in people with Alzheimer's disease from less common forms of dementia that have distinct anatomical changes in the brain. If successful, the present work will provide a new means to track the early stages of neurodegeneration as would be used in clinical trials and translational medical research. Terms: <AD dementia><Acceleration><Achievement><Achievement Attainment><Affect><Age><Aging><Alzheimer Type Dementia><Alzheimer beta-Protein><Alzheimer disease dementia><Alzheimer sclerosis><Alzheimer syndrome><Alzheimer's><Alzheimer's Amyloid beta-Protein><Alzheimer's Disease><Alzheimer's amyloid><Alzheimers Dementia><Amentia><American><Ammon Horn><Amyloid Alzheimer's Dementia Amyloid Protein><Amyloid Beta-Peptide><Amyloid Protein A4><Amyloid beta-Protein><Amyloid β><Amyloid β-Peptide><Amyloid β-Protein><Anatomic Sites><Anatomic structures><Anatomy><Atrophic><Atrophy><Aβ><Base Sequence><Biological Markers><Brain><Brain Nervous System><Brain imaging><Brain region><Brain scan><Clinic><Clinical><Clinical Trials><Clinical assessments><Cognitive Disturbance><Cognitive Impairment><Cognitive decline><Cognitive function abnormal><Cornu Ammonis><Data><Dementia><Development><Diagnosis><Disease><Disorder><Disturbance in cognition><Early identification><Encephalon><Event><Focus Groups><Goals><Head><Hippocampus><Human><Imaging Procedures><Imaging Technics><Imaging Techniques><Impaired cognition><Individual><Joints><MR Imaging><MR Tomography><MRI><MRI Scans><MRIs><MT-bound tau><Machine Learning><Magnetic Resonance Imaging><Magnetic Resonance Imaging Scan><Maritally Unattached><Measurement><Measures><Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance><Medical Research><Memory Deficit><Memory impairment><Mesulam Syndrome><Methodology><Modeling><Modern Man><Monitor><NMR Imaging><NMR Tomography><Nerve Degeneration><Neuron Degeneration><Neurosciences Research><Nuclear Magnetic Resonance Imaging><Nucleotide Sequence><Pathology><Pattern><Persons><Phase><Position><Positioning Attribute><Primary Progressive Aphasia><Primary Senile Degenerative Dementia><Probabilistic Models><Probability Models><Procedures><Progressive Aphasias><Protocol><Protocols documentation><Proxy><Research><Resolution><Safety><Sampling><Scanning><Semantics><Single Person><Statistical Models><Stream><Structure><Techniques><Testing><Therapeutic Effect><Thick><Thickness><Time><Unmarried person><Variant><Variation><Work><Zeugmatography><a beta peptide><abeta><ages><aging associated><aging related><amnestic mild cognitive impairment><amyloid beta><amyloid-b protein><beta amyloid fibril><bio-markers><biologic marker><biomarker><brain atrophy><brain visualization><brain volume><cerebral atrophy><clinical translation><clinically translatable><cognitive change><cognitive dysfunction><cognitive loss><cortical atrophy><developmental><hippocampal><hippocampal atrophy><hippocampal atropy><image construction><image generation><image reconstruction><imaging approach><imaging based approach><machine based learning><memory dysfunction><microtubule bound tau><microtubule-bound tau><morphometry><natural aging><neural degeneration><neural imaging><neuro-imaging><neurodegeneration><neurodegenerative><neuroimaging><neurological degeneration><neurological imaging><neuronal degeneration><normal aging><normative aging><novel><nucleic acid sequence><pre-clinical><preclinical><primary degenerative dementia><rate of change><resolutions><response to therapy><response to treatment><safety testing><secondary analysis><senile dementia of the Alzheimer type><soluble amyloid precursor protein><statistical linear mixed models><statistical linear models><structural imaging><tau><tau Proteins><tau factor><therapeutic agent development><therapeutic development><therapeutic response><therapy response><time interval><tool><treatment response><treatment responsiveness><τ Proteins>